726.33
+33.745(+4.87%)
Currency In USD
| Previous Close | 692.58 |
| Open | 695.06 |
| Day High | 728 |
| Day Low | 692.5 |
| 52-Week High | 790.98 |
| 52-Week Low | 476.49 |
| Volume | 858,238 |
| Average Volume | 1.09M |
| Market Cap | 75B |
| PE | 17.42 |
| EPS | 41.69 |
| Moving Average 50 Days | 651.73 |
| Moving Average 200 Days | 598.9 |
| Change | 33.63 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) 10 years ago, it would be worth $1,358.86 as of December 11, 2025 at a share price of $726.325. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 5 years ago, it would be worth $1,513.9 as of December 11, 2025 at a share price of $726.325.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investm
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
GlobeNewswire Inc.
Nov 19, 2025 9:10 PM GMT
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patient care TAR
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
GlobeNewswire Inc.
Oct 12, 2025 2:18 PM GMT
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improvement in their hearing Among three who completed s